CS
VERV

Credit Suisse’s Verve Therapeutics VERV Stock Holding History

Credit Suisse’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$873K Buy
65,742
+2,889
+5% +$38.3K ﹤0.01% 2344
2023
Q4 		$876K Buy
62,853
+13,196
+27% +$164K ﹤0.01% 2417
2023
Q3 		$658K Sell
49,657
-4,689
-9% -$75.5K ﹤0.01% 2535
2023
Q2 		$1.02M Buy
54,346
+15,800
+41% +$263K ﹤0.01% 2368
2023
Q1 		$556K Buy
38,546
+1,841
+5% +$36K ﹤0.01% 2692
2022
Q4 		$710K Buy
36,705
+8,061
+28% +$214K ﹤0.01% 2570
2022
Q3 		$984K Buy
28,644
+16,111
+129% +$514K ﹤0.01% 2349
2022
Q2 		$191K Buy
12,533
+412
+3% +$6.38K ﹤0.01% 3346
2022
Q1 		$276K Buy
12,121
+1,251
+12% +$35.8K ﹤0.01% 3262
2021
Q4 		$402K Buy
+10,870
New +$457K ﹤0.01% 3972

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Credit Suisse's VERV Position: Q1 2024 in Review

Credit Suisse increased its Verve Therapeutics (VERV) stake by 4.6% in Q1 2024, buying an estimated $38.3K and bringing the position to 65,742 shares worth $873K. The position accounts for ﹤0.01% of the portfolio, ranked #2344.

Credit Suisse first reported a position in VERV in Q4 2021 and has held it in 10 quarters since. The position peaked at $1.02M in Q2 2023. 163 funds tracked by Wall St. Rank hold VERV as of Q1 2024.

  • Credit Suisse held 65,742 shares of Verve Therapeutics worth $873K as of Q1 2024.
  • Credit Suisse bought 2,889 Verve Therapeutics shares in Q1 2024, an estimated $38.3K.
  • Verve Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2344 holding.
  • Credit Suisse first reported a position in Verve Therapeutics in Q4 2021 and has held it in 10 quarters since.
  • Credit Suisse's Verve Therapeutics position peaked at $1.02M in Q2 2023.
  • 163 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.